Overview of Viscoat

What Type of Medical Product is Viscoat?

Viscoat is classified as an Ophthalmic Viscosurgical Device (OVD). It functions as a specialized, sterile agent used for intraocular procedures, acting as a surgical aid rather than a traditional drug that alters body chemistry. This classification reflects its role in providing mechanical support during delicate eye surgery. It belongs to the pharmacological class of a viscoelastic agent, defined by its specific physical properties. These viscoelastic solutions, administered intraocularly, are used to maintain space and provide physical protection within the eye during operations.

What is Viscoat Made Of? Composition and Unique Features

Viscoat is a combination product composed of two core active ingredients: Sodium Hyaluronate and Chondroitin Sulfate. Both components are high-molecular-weight biological polymers belonging to the class of Glucosaminoglycans. The preparation is manufactured as a sterile ophthalmic solution delivered in an aqueous vehicle. The combination of these two polymers creates a specific rheological balance designed to deliver enhanced protection. Unlike single-component OVDs, this dual formulation offers a dispersive characteristic, allowing it to adhere to and coat sensitive internal tissues. This formulation is intended to provide sustained protection for the cells of the corneal endothelium throughout the surgical phase.

What is the General Purpose of This Viscoelastic Agent?

The general purpose of Viscoat is to provide space maintenance and physical protection to critical internal eye structures during surgery. Its viscoelasticity allows the agent to temporarily stabilize the surgical field, helping to prevent the collapse of the anterior chamber while facilitating tissue separation. Its primary function is creating a sustained protective barrier, or dispersive layer, which shields sensitive cells from physical stress caused by surgical instruments or irrigation flow. This mechanical action helps maintain the integrity of the eye's tissues throughout the critical phases of an ophthalmic procedure.

Regulatory References

What side effects are possible with Viscoat?

Possible Side Effects and Safety Information

The safety profile for Viscoat is documented based on its function as an Ophthalmic Viscosurgical Device (OVD) used during anterior segment surgery. Adverse reactions are primarily classified within the Eye disorders system-organ class, reflecting the site of use.

Documented Adverse Reactions

The most commonly reported adverse event is a transient postoperative increase in intraocular pressure (IOP), which is typically linked to the temporary retention of the viscoelastic material. Other adverse events noted in regulatory summaries include postoperative inflammatory reactions, such as iritis or hypopyon, as well as corneal edema and pain.

Serious Safety Concerns

Official regulatory documents identify several serious adverse reactions associated with the use of OVDs. These include severe inflammatory conditions like Toxic Anterior Segment Syndrome (TASS), postoperative endophthalmitis (intraocular infection), and the potential for corneal decompensation or severe vision loss. These events, while rare, are considered clinically significant.

Safety Restrictions and Population Considerations

Safety is highly dependent on proper surgical procedure. A critical safety restriction is the requirement for the complete removal of the product from the eye at the end of the procedure to mitigate the risk of elevated IOP. The safety profile also includes specific considerations for patients with pre-existing glaucoma, as they are noted to be at an increased risk for significant postoperative IOP spikes. Additionally, the product should not come into contact with instruments that have been exposed to quaternary ammonium salts, as this can cause precipitation of the viscoelastic material.

Overdose and Emergency Response

Overdose and When to Seek Help

Viscoat is an Ophthalmic Viscosurgical Device (OVD), and the concept of 'overdose' applies to the use or retention of an excess quantity of the material within the eye, not a systemic drug overdose.

Regulatory documents emphasize that the primary risk associated with over-exposure or failure to fully remove the OVD after surgery is a postoperative increase in intraocular pressure (IOP). This pressure elevation is considered a potentially serious complication resulting from the material obstructing the outflow pathway in the eye.

Overdose Context and Manifestations

Overdose Presentation	Physiological System Affected
Increased intraocular pressure (IOP)	Ocular/Visual System
Intraocular inflammation (e.g., TASS)	Ocular/Visual System
Potential for Vision Loss	Ocular/Visual System

Required Emergency Actions

The most important action is to remove the OVD from the anterior chamber at the conclusion of the surgical procedure to prevent or minimize the risk of a postoperative IOP rise. Since increased IOP can lead to complications such as inflammation and potentially vision loss, patients must seek urgent medical attention immediately if they experience a significant change in eyesight, severe eye pain, or very bad eye irritation after the procedure. All potentially sight-threatening complications must be reported to the appropriate healthcare providers and regulatory bodies.

Therapeutic Uses of Viscoat

Viscoat: Main Uses and Benefits

Viscoat (sodium chondroitin sulfate–sodium hyaluronate) is a surgical aid employed in ophthalmic anterior segment procedures. It is primarily indicated for use during surgery, such as cataract extraction and the implantation of an intraocular lens (IOL).

Quick Facts

Therapeutic Domain: Assists in ophthalmic surgical procedures.
Main Uses: Facilitates cataract removal and IOL placement.
Key Function: Supports the maintenance of space within the anterior chamber of the eye.

During these delicate procedures, the solution assists in maintaining a deep anterior chamber, which helps support the surgeon’s visualization of the surgical site. Its formulation is designed to provide a measure of protection to intraocular tissues, including the corneal endothelium and surrounding ocular structures, throughout the surgical process. The use of this preparation is an established component of modern anterior segment surgical care.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Viscoat

Viscoat is officially classified as an Ophthalmic Viscosurgical Device (OVD), and its eligibility profile focuses on local reactions and established use populations.

Category	Official Regulatory Statement
Populations for whom use is allowed:	Patients undergoing ophthalmic anterior segment procedures, such as cataract extraction and intraocular lens (IOL) implantation.
Populations for whom use is contraindicated:	Patients with known hypersensitivity (allergy) to any component of the OVD.
Age-related eligibility rules:	Use is not established in pediatric patients. Use is established in the adult and older adult populations for the indicated procedures.
Pregnancy and lactation eligibility status:	Safety and effectiveness have not been established in pregnant women or lactating/nursing mothers.
Eligibility-related restrictions:	Use requires special caution and monitoring in patients with pre-existing glaucoma or ocular hypertension.

The regulatory profile defines eligibility primarily by exclusion, prohibiting use due to component hypersensitivity. The safety and effectiveness status is officially classified as "not established" for pediatric, pregnant, and lactating populations. Use is otherwise documented for the adult population undergoing specific ophthalmic procedures, with required precautions noted for patients with pre-existing ocular hypertension due to the risk of transient postoperative intraocular pressure spikes.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Viscoat is defined by its classification as an Ophthalmic Viscosurgical Device (OVD) that is administered directly into the eye (intraocular route). This local, mechanical function results in negligible systemic exposure, which fundamentally limits the potential for conventional drug interactions.

Systemic Pharmacokinetic Status Official regulatory labeling does not document any systemic pharmacokinetic or pharmacodynamic interactions with co-administered medicines or substances. This absence of established interaction is consistent with the product's method of administration. Consequently, no restrictions are necessary for the following:

Interacting Medicines: No medicinal products are specifically listed as requiring mandatory dose adjustments or prohibition due to systemic interaction risk with Viscoat.
Metabolic Pathways: No concerns are documented regarding interactions with drug-metabolizing enzymes (such as CYP enzymes) or drug transporters in official prescribing information.
Food, Alcohol, or Supplements: No interactions with food, alcohol, or herbal products are described in official labeling.

Procedural and Local Constraints Interaction concerns are confined to procedural chemical compatibility within the surgical field. A key restriction is documented to ensure local chemical integrity: the product must avoid contact with surgical instruments sterilized using quaternary ammonium salt solutions. This procedural constraint is essential for preventing potential chemical incompatibility within the ocular environment during the surgical process.

Mechanism of Action

Viscoat functions solely via its physico-chemical and rheological properties as a specialized mechanical aid, rather than modulating classical biochemical targets. Its mechanism begins with a surface charge interaction where the solution's dual-polymer structure creates a net negative charge. This charge adheres tightly via electrostatic attraction to the positively charged surface of the corneal endothelium . This adherence establishes a persistent physical barrier that prevents the propagation of mechanical shear stress and direct physical trauma to the cells, physically maintaining the separation necessary for endothelial cellular integrity.

Simultaneously, the material's viscoelasticity establishes temporary spatial volume within the anterior chamber, causing a temporary volume displacement that stabilizes shape and depth. This stable architecture results in increased resistance to internal pressure fluctuations. Furthermore, the dispersive nature of the formulation ensures the solution spreads broadly, modulating intraocular fluid dynamics by resisting high flow rates. This retained physical coating establishes sustained mechanical resistance, influencing the localized mechanical environment that modulates the intensity of physical forces exerted on tissues

Dosage and Administration Information

How to Use Viscoat: Administration Guidelines

Viscoat (sodium chondroitin sulfate and sodium hyaluronate) is a sterile ophthalmic viscosurgical device (OVD), and its use is confined to the acute surgical setting. These guidelines govern its role as a temporary aid during anterior segment ophthalmic procedures, such as cataract extraction and intraocular lens (IOL) implantation.

Administration Scope

Property	Description
Route of Administration	Intraocular administration. The solution is infused directly into the anterior chamber of the eye.
Dosing Schedule	Sufficient volume is infused to maintain space and protect tissues. Volume is determined by the need to facilitate the surgical procedure.
Preparation Requirements	The product, if refrigerated, should be allowed to reach room temperature prior to use to ensure proper physical properties.
Age-Group Rules	Not specified in labeling for dose adjustment, as the product's use is non-systemic and procedural.

Instruction Classifications

Classification	Description
Administration Method Type	Injection/Infusion (Intraocular).
Frequency Pattern	Single-use per operative procedure.
Regulatory Basis	National regulatory standards.
Use-Context Constraints	Must be used only in a sterile surgical setting by trained ophthalmic personnel.

Resulting Procedural Structure

Standard procedural instructions specify that a sufficient volume of the solution is infused into the anterior chamber, typically prior to cataract extraction. The entire contents of the syringe are for single use only, and any unused portion must be discarded. Critically, the device must be removed from the anterior chamber by irrigation and/or aspiration at the conclusion of the surgery. This confirms that its use is temporary, lasting only the duration of the procedure.

Recent Clinical Evidence

Research evidence / Overview of studies for Viscoat

Evidence for Use in Cataract Extraction and IOL Implantation

Viscoat is a specialized surgical aid that was evaluated in studies exploring its use in procedures like cataract extraction and intraocular lens (IOL) implantation. The core research involves Randomized Controlled Trials (RCTs), where the use of Viscoat is compared to other types of surgical agents, known as Ophthalmic Viscosurgical Devices (OVDs). Researchers in these trials focused on examining the device’s physical role and its association with tissue preservation in the delicate structures inside the eye.

Specifically, research examined outcomes related to Corneal Endothelial Cell Density (ECD), which is a key measure of cell change in this critical layer of cells at the front of the eye. Studies monitored changes in the density of these cells (a measure of cell loss) and any changes in the thickness of the cornea (a measure of swelling) at defined follow-up times after the operation. This evidence was observed in adult populations undergoing routine, non-complicated cataract surgery.

Comparative Research on Ophthalmic Viscosurgical Devices (OVDs)

Many studies were evaluated in trials that compared Viscoat, which is a combination of two polymers (sodium chondroitin sulfate and sodium hyaluronate), against single-polymer OVDs. Studies explored the comparative measurement of outcomes when this dual-polymer formulation was used versus other agents.

These studies monitored outcomes related to physical discomfort and functional imbalance, particularly monitoring Intraocular Pressure (IOP). Findings describe patterns observed in the studies regarding temporary IOP spikes in the first hours or days after surgery. Some comparative trials described an association where the use of Viscoat was observed in some studies to be linked to a statistically higher incidence of early postoperative IOP spikes compared to certain cohesive OVDs. This finding describes an association that has been observed in some studies when comparing the use of dispersive agents like Viscoat versus other OVD classes.

Research on Post-Surgical Outcomes and Follow-up Duration

Clinical trials for Viscoat were applied in research contexts involving the immediate postoperative period. The primary endpoints studied—corneal cell density and thickness—were typically evaluated at short-term follow-up durations, such as one month and three months after the cataract procedure. The available research mostly examines tissue responses and change patterns over the course of short-term or intermediate periods, providing limited insight into the long-term effects of the surgical aid on the eye's tissues.

What is Still Uncertain About Viscoat Research

The research landscape for Viscoat has several areas where the data are still emerging or where certainty remains low. Long-term effects are not fully established, as there is limited information for long-term outcomes beyond the initial three-month postoperative window. Furthermore, while the evidence quality varies across studies, the reported patterns of early postoperative IOP spikes remain a subject of research, especially when determining how these patterns apply to individuals who may have a higher risk of pressure fluctuations.

Key Studies & References

Evaluation of endothelial cell changes and intraocular pressure following cataract extraction and intraocular lens implantation with chondroitin sulfate-sodium hyaluronate

Frequently Asked Questions (FAQ)

Common questions about Viscoat (FAQ)

Q: How does Viscoat compare to other gel-like substances used in eye surgery?

According to official sources, Viscoat is classified as a dispersive Ophthalmic Viscosurgical Device (OVD). This classification means it has physical properties that allow it to spread broadly to coat and protect tissues, consistent with its classification. It is also distinguished by its dual-polymer composition, containing both sodium hyaluronate and sodium chondroitin sulfate.

Q: Is Viscoat used in all types of cataract surgery?

Official regulatory indications specify that the device is approved as a surgical aid for anterior segment ophthalmic procedures. This includes ophthalmic anterior segment procedures, such as cataract extraction and intraocular lens (IOL) implantation.

Q: Is it normal for my eye pressure to feel slightly different immediately after surgery involving Viscoat?

Official adverse event summaries indicate that the most commonly reported event is a transient (temporary) increase in intraocular pressure (IOP) shortly after the procedure. This temporary rise is linked to the material's temporary retention, which is why official guidelines mandate the device's complete removal at the end of surgery.

Q: Are there any long-term side effects associated with Viscoat?

Official research overviews indicate that data regarding the long-term effects of the device are limited. The available studies primarily examine patient outcomes over the short-term and intermediate periods following the procedure.

Q: What kind of discomfort should I watch out for that might be related to Viscoat?

Regulatory safety summaries note adverse events in the eye such as pain, corneal edema (swelling of the clear front layer of the eye), and postoperative inflammatory reactions (like iritis or hypopyon).

Q: Is Viscoat used for eye conditions/procedures other than cataracts?

The official regulatory indication is for use as a surgical aid in anterior segment ophthalmic procedures, including cataract extraction and intraocular lens implantation. Official documents do not explicitly list indications for other specific conditions or procedures.

Q: Is the use of Viscoat supported by a lot of medical studies?

Studies, including Randomized Controlled Trials (RCTs), have evaluated the device, focusing on its role in protecting eye tissue during surgery. Official overviews note that while evidence exists, the quality of this evidence is described as varying across studies.

Q: What happens if some Viscoat remains in the eye after the operation?

The regulatory profile requires the device to be completely removed from the eye at the conclusion of surgery. This mandatory step is required to mitigate the risk of a transient postoperative increase in intraocular pressure (IOP), which is associated with temporary retention of the material.

Q: Is Viscoat the same as hyaluronic acid injections?

Viscoat is a combination product containing both sodium hyaluronate and chondroitin sulfate. It is officially classified as an Ophthalmic Viscosurgical Device (OVD) and functions as a surgical aid placed inside the eye during a procedure. It is not the same as general hyaluronic acid injections, as it is classified as a sterile, temporary surgical aid.

Q: How is Viscoat different from an air bubble or saline solution used in the eye?

Viscoat is classified as a viscoelastic agent due to its unique physical properties. These properties enable the device to offer mechanical support and physical protection to eye tissues, consistent with its design to create temporary space and stabilize the surgical environment.

Q: What is the shelf life of the product Viscoat?

Regulatory documents specify that the approved shelf life of the product is 24 months from the date of manufacture.

Q: Does Viscoat come pre-filled, or does the doctor prepare it?

The product is supplied in a sterile, single-use syringe ready for the procedure. Regulatory guidelines mandate that any remaining portion must be discarded immediately after the operation.

Q: What does 'pseudo-cohesive' mean in relation to Viscoat?

Viscoat is officially characterized by its dispersive properties. This means the material is intended to spread broadly and adhere closely to sensitive tissues inside the eye, consistent with its function to maintain a protective physical coating during the procedure.

Q: Will I need to do anything special before surgery because Viscoat is being used?

Official administration guidelines primarily contain instructions for the surgical team regarding product preparation, such as allowing the refrigerated material to reach room temperature before use. They do not specify any required pre-operative steps or actions that the patient needs to take specifically because Viscoat will be used.

Q: Why is the molecular weight of the components in Viscoat important?

The active components are described as high-molecular-weight biological polymers. This characteristic contributes to the device’s viscoelasticity (its ability to flow and stretch) and its ability to adhere to tissues, supporting its role in providing physical protection during the operation.

Q: Does the use of Viscoat have anything to do with my existing medical history?

The official eligibility profile requires special consideration for two main historical factors: a known history of hypersensitivity (allergy) to any component of the device, and a history of pre-existing glaucoma or ocular hypertension. These are the primary factors noted in the regulatory documents related to a patient’s medical background.

How should Viscoat be stored and disposed of?

Mandatory Storage and Protection

Viscoat (sodium chondroitin sulfate–sodium hyaluronate) must be stored in a refrigerator within the temperature range of 2 C to 8 C (36 F to 46 F). It is mandatory to protect the product from freezing; freezing compromises the product's shelf-life guarantee. Additionally, the product must be protected from light and stored in its original, undamaged sterile package.

Handling and Disposal Requirements

Prior to use, the refrigerated product should be allowed to reach room temperature (approximately 20 to 45 minutes). The product is designated for single use only. Once the container is opened, any unused portion or contaminated equipment must be discarded immediately. Disposal of the material and packaging must follow applicable safe disposal procedures and laws regarding the disposal of biohazardous materials.

Viscoat